Let's look at cysts from both sides now

Kidney International

Volumn 74, Issue 6, 2008, Pages 699-702

  Alper, Seth L ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,2 BIS(4 FLUOROPHENYL) 2 PHENYLACETAMIDE; CLOTRIMAZOLE; CLOTRIMAZOLE DERIVATIVE; DIGOXIN; FORSKOLIN; IMIDAZOLE DERIVATIVE; LOOP DIURETIC AGENT; NYSTATIN; OCTREOTIDE; POTASSIUM CHANNEL; POTASSIUM CHANNEL BLOCKING AGENT; RAPAMYCIN; ROSCOVITINE; TRAM 34;

CELL CYCLE; DRUG EFFECT; GROWTH INHIBITION; HUMAN; HYPERTENSION; ION TRANSPORT; KIDNEY EPITHELIUM; KIDNEY POLYCYSTIC DISEASE; LIVER FUNCTION TEST; NOTE; PRIORITY JOURNAL; SIDE EFFECT; UNSPECIFIED SIDE EFFECT;

EID: 50849105382     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2008.357     Document Type: Note

References (27)

1. Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet 2007; 369: 1287-1301.
2. Grantham JJ, Cook LT, Torres VE et al. Determinants of renal volume in autosomal-dominant polycystic kidney disease. Kidney Int 2008; 73: 108-116.
3. Albaqumi M, Srivastava S, Li Z et al. KCa3.1 potassium channels are critical for cAMP-dependent chloride secretion and cyst growth in autosomal-dominant polycystic kidney disease. Kidney Int 2008; 74: 740-749.
4. Sullivan LP, Wallace DP, Grantham JJ. Epithelial transport in polycystic kidney disease. Physiol Rev 1998; 78: 1165-1191.
5. Wang X, Wu Y, Ward CJ et al. Vasopressin directly regulates cyst growth in polycystic kidney disease. J Am Soc Nephrol 2008; 19: 102-108.
6. Ruggenenti P, Remuzzi A, Ondei P et al. Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. Kidney Int 2005; 68: 206-216.
7. Xu N, Glockner JF, Rossetti S et al. Autosomal dominant polycystic kidney disease coexisting with cystic fibrosis. J Nephrol 2006; 19: 529-534.
8. Ma T, Thiagarajah JR, Yang H et al. Thiazolidinone CFTR inhibitor identified by high-throughput screening blocks cholera toxin-induced intestinal fluid secretion. J Clin Invest 2002; 110: 1651-1658.
9. Muanprasat C, Sonawane ND, Salinas D et al. Discovery of glycine hydrazide pore-occluding CFTR inhibitors: mechanism, structure-activity analysis, and in vivo efficacy. J Gen Physiol 2004; 124: 125-137.
10. Yang B, Sonawane ND, Zhao D et al. Small-molecule CFTR inhibitors slow cyst growth in polycystic kidney disease. J Am Soc Nephrol 2008; 19: 1300-1310.
11. Augarten A, Tov AB, Madgar I et al. The changing face of the exocrine pancreas in cystic fibrosis: the correlation between pancreatic status, pancreatitis and cystic fibrosis genotype. Eur J Gastroenterol Hepatol 2008; 20: 164-168.
12. Brugnara C, De Franceschi L, Alper SL. Ca(2+)-activated K+ transport in erythrocytes. Comparison of binding and transport inhibition by scorpion toxins. J Biol Chem 1993; 268: 8760-8768.
13. Vandorpe DH, Shmukler BE, Jiang L et al. cDNA cloning and functional characterization of the mouse Ca2+-gated K+ channel, mIK1. Roles in regulatory volume decrease and erythroid differentiation. J Biol Chem 1998; 273: 21542-21553.
14. Ishii TM, Silvia C, Hirschberg B et al. A human intermediate conductance calcium-activated potassium channel. Proc Natl Acad Sci USA 1997; 94: 11651-11656.
15. Brugnara C, Gee B, Armsby CC et al. Therapy with oral clotrimazole induces inhibition of the Gardos channel and reduction of erythrocyte dehydration in patients with sickle cell disease. J Clin Invest 1996; 97: 1227-1234.
16. Brugnara C, Armsby CC, Sakamoto M et al. Oral administration of clotrimazole and blockade of human erythrocyte Ca(++)-activated K+ channel: the imidazole ring is not required for inhibitory activity. J Pharmacol Exp Ther 1995; 273: 266-272.
17. Wulff H, Kolski-Andreaco A, Sankaranarayanan A et al. Modulators of small- and intermediate-conductance calcium-activated potassium channels and their therapeutic indications. Curr Med Chem 2007; 14: 1437-1457.
18. Ataga KI, Smith WR, De Castro LM et al. Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia. Blood 2008; 111: 3991-3997.
19. Joiner CH. Gardos pathway to sickle cell therapies? Blood 2008; 111: 3918-3919.
20. Begenisich T, Nakamoto T, Ovitt CE et al. Physiological roles of the intermediate conductance, Ca2+-activated potassium channel Kcnn4. J Biol Chem 2004; 279: 47681-47687.
21. Flores CA, Melvin JE, Figueroa CD, Sepulveda FV. Abolition of Ca2+-mediated intestinal anion secretion and increased stool dehydration in mice lacking the intermediate conductance Ca2+-dependent K+ channel Kcnn4. J Physiol 2007; 583: 705-717.
22. Si H, Heyken WT, Wolfle SE et al. Impaired endothelium-derived hyperpolarizing factor-mediated dilations and increased blood pressure in mice deficient of the intermediate-conductance Ca2+-activated K+ channel. Circ Res 2006; 99: 537-544.
23. Rufo PA, Jiang L, Moe SJ et al. The antifungal antibiotic, clotrimazole, inhibits Cl- secretion by polarized monolayers of human colonic epithelial cells. J Clin Invest 1996; 98: 2066-2075.
24. Devor DC, Singh AK, Gerlach AC et al. Inhibition of intestinal Cl- secretion by clotrimazole: direct effect on basolateral membrane K+ channels. Am J Physiol 1997; 273: C531-C540.
25. Devor DC, Singh AK, Lambert LC et al. Bicarbonate and chloride secretion in Calu-3 human airway epithelial cells. J Gen Physiol 1999; 113: 743-760.
26. Chou CC, Lunn CA, Murgolo NJ. KCa3.1: target and marker for cancer, autoimmune disorder and vascular inflammation? Expert Rev Mol Diagn 2008; 8: 179-187.
27. Tharp DL, Wamhoff BR, Wulff H et al. Local delivery of the KCa3.1 blocker, TRAM-34, prevents acute angioplasty-induced coronary smooth muscle phenotypic modulation and limits stenosis. Arterioscler Thromb Vasc Biol 2008; 28: 1084-1089.